HomeAbout

TL;DR CNBC


In high-stakes votes, FDA advisors say evidence doesn't back Philip Morris' claims - TL;DR CNBC

In high-stakes votes, FDA advisors say evidence doesn't back Philip Morris' claims

Publishing timestamp: 2018-01-26 01:03:00


Summary

Philip Morris International presented its case to an independent advisory committee seeking FDA approval to market its heat-not-burn tobacco product, iQOS, as safer than cigarettes. The committee rejected PMI's claims that iQOS cuts the risk of tobacco-related diseases and is likely to switch adult cigarette smokers. Analysts remain optimistic about FDA approval, despite concerns raised by the committee. PMI's shares closed down 2.8 percent.


Sentiment: MIXED

Tickers: MOPM

Keywords: health care industrybusiness newsaltria group incphilip morris international inc

Source: https://www.cnbc.com/2018/01/25/philip-morris-stock-falls-as-committee-reviews-iqos-claims.html


Developed by Leo Phan